The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Apr 20

PMID 31001269

Citations 7

Authors

Gary L Norman

Anna Reig

Odette Vinas

Michael Mahler

Ewa Wunsch

Piotr Milkiewicz

Mark G Swain

Andrew Mason

Laura M Stinton

Maria Belen Aparicio

Maria Jose Aldegunde

Marvin J Fritzler

Albert Pares

Affiliations

Soon will be listed here.

Abstract

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is present worldwide. Autoantibodies, in particular anti-mitochondrial antibodies (AMA) detected by indirect immunofluorescence assays or newer solid phase immunoassays can detect most, but not all individuals with PBC. Detection of antibodies to the anti-nuclear antigens sp100 and gp210 can identify additional PBC patients, but some seronegative patients remain, often resulting in delayed diagnosis and treatment. Antibodies to kelch-like 12 (KLHL12) and hexokinase 1 (HK-1) were recently identified as new biomarkers for PBC and notably identify patients who are negative for conventional autoantibodies. To become globally adopted, it is important to validate these new biomarkers in different geographic areas. In the present study we evaluated the prevalence of anti-KLHL12 (measured by a KLHL12-derived peptide referred to as KL-p) and anti-HK-1 antibodies by ELISA at five sites within Europe and North America and demonstrated the presence of these antibodies in patients with PBC in all geographies.

Citing Articles

Role of autoantibodies in the clinical management of primary biliary cholangitis.

Rigopoulou E, Bogdanos D World J Gastroenterol. 2023; 29(12):1795-1810.

PMID: 37032725 PMC: 10080701. DOI: 10.3748/wjg.v29.i12.1795.

Short-term exposure to fine particulate matter and genome-wide DNA methylation in chronic obstructive pulmonary disease: A panel study conducted in Beijing, China.

Duan R, Niu H, Dong F, Yu T, Li X, Wu H Front Public Health. 2023; 10:1069685.

PMID: 36684947 PMC: 9850166. DOI: 10.3389/fpubh.2022.1069685.

Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years.

Chang M, Chen W, Chan T, Lin C, Chang M, Chen S Front Immunol. 2022; 13:869018.

PMID: 35663951 PMC: 9160714. DOI: 10.3389/fimmu.2022.869018.

Diagnostic and Clinical Value of Specific Autoantibodies against Kelch-like 12 Peptide and Nuclear Envelope Proteins in Patients with Primary Biliary Cholangitis.

Bauer A, Habior A, Gawel D Biomedicines. 2022; 10(4).

PMID: 35453551 PMC: 9029829. DOI: 10.3390/biomedicines10040801.

Working Algorithms and Detection Methods of Autoantibodies in Autoimmune Liver Disease: A Nationwide Study.

Munoz-Sanchez G, Perez-Isidro A, de Landazuri I, Lopez-Gomez A, Bravo-Gallego L, Garcia-Ormaechea M Diagnostics (Basel). 2022; 12(3).

PMID: 35328252 PMC: 8947365. DOI: 10.3390/diagnostics12030697.

References

Miyakawa H, Tanaka A, Kikuchi K, Matsushita M, Kitazawa E, Kawaguchi N . Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology. 2001; 34(2):243-8. DOI: 10.1053/jhep.2001.26514. View

Prince M, Chetwynd A, Newman W, Metcalf J, James O . Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002; 123(4):1044-51. DOI: 10.1053/gast.2002.36027. View

Walker J, Doniach D, Roitt I, Sherlock S . SEROLOGICAL TESTS IN DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS. Lancet. 1965; 1(7390):827-31. DOI: 10.1016/s0140-6736(65)91372-3. View

Muratori P, Muratori L, Gershwin M, Czaja A, Pappas G, MacCariello S . 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. Clin Exp Immunol. 2003; 135(1):154-8. PMC: 1808914. DOI: 10.1111/j.1365-2249.2004.02332.x. View

Brooks Robey R, Hay N . Mitochondrial hexokinases: guardians of the mitochondria. Cell Cycle. 2005; 4(5):654-8. DOI: 10.4161/cc.4.5.1678. View

Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J . Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis. 2005; 25(3):298-310. DOI: 10.1055/s-2005-916321. View

Wesierska-Gadek J, Penner E, Battezzati P, Selmi C, Zuin M, Hitchman E . Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006; 43(5):1135-44. DOI: 10.1002/hep.21172. View

Milkiewicz P, Buwaneswaran H, Coltescu C, Shums Z, Norman G, Heathcote E . Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin Gastroenterol Hepatol. 2009; 7(12):1355-60. DOI: 10.1016/j.cgh.2009.07.012. View

Liu H, Norman G, Shums Z, Worman H, Krawitt E, Bizzaro N . PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010; 35(4):436-42. DOI: 10.1016/j.jaut.2010.09.005. View

10.

Boonstra K, Beuers U, Ponsioen C . Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012; 56(5):1181-1188. DOI: 10.1016/j.jhep.2011.10.025. View

11.

Hu C, Song G, Huang W, Liu G, Deng C, Zeng H . Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics. 2012; 11(9):669-80. PMC: 3434773. DOI: 10.1074/mcp.M111.015529. View

12.

Hirschfield G, Gershwin M . The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol. 2013; 8:303-30. DOI: 10.1146/annurev-pathol-020712-164014. View

13.

Dhanoa B, Cogliati T, Satish A, Bruford E, Friedman J . Update on the Kelch-like (KLHL) gene family. Hum Genomics. 2013; 7:13. PMC: 3658946. DOI: 10.1186/1479-7364-7-13. View

14.

Gupta V, Beggs A . Kelch proteins: emerging roles in skeletal muscle development and diseases. Skelet Muscle. 2014; 4:11. PMC: 4067060. DOI: 10.1186/2044-5040-4-11. View

15.

Norman G, Yang C, Ostendorff H, Shums Z, Lim M, Wang J . Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int. 2014; 35(2):642-51. PMC: 4305042. DOI: 10.1111/liv.12690. View

16.

Chan E, Damoiseaux J, Carballo O, Conrad K, Cruvinel W, Francescantonio P . Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. Front Immunol. 2015; 6:412. PMC: 4542633. DOI: 10.3389/fimmu.2015.00412. View

17.

Beuers U, Gershwin M, Gish R, Invernizzi P, Jones D, Lindor K . Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Hepatology. 2015; 62(5):1620-2. DOI: 10.1002/hep.28140. View

18.

Dahlqvist G, Gaouar F, Carrat F, Meurisse S, Chazouilleres O, Poupon R . Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology. 2016; 65(1):152-163. DOI: 10.1002/hep.28859. View

19.

Muratori P, Muratori L . Autoantibodies in antimithocondrial antibodies negative primary biliary cholangitis. Clin Res Hepatol Gastroenterol. 2017; 41(4):e47. DOI: 10.1016/j.clinre.2017.04.016. View

20.

Cheung K, Seto W, Fung J, Lai C, Yuen M . Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017; 8(8):e116. PMC: 5587844. DOI: 10.1038/ctg.2017.43. View